MRVI Q2 2025 Earnings — Maravai LifeSciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

MRVIMaravai LifeSciences Holdings, Inc.

$999M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$47M-35.4% YoY

Gross Profit

$8M16.4% margin

Operating Income

-$66M-139.8% margin

Net Income

-$40M-83.5% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

+1.2%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$13M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$897M

Total Liabilities

$429M

Stockholders' Equity

$266M

Cash & Equivalents

$270M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$47M	$73M	-35.4%
Gross Profit	$8M	$35M	-77.9%
Operating Income	-$66M	-$10M	-596.8%
Net Income	-$40M	-$8M	-422.0%

Revenue Segments

Nucleic Acid Production Segment

$31M66%

Biologics Safety Testing Segment

$16M34%

Geographic Segments

North America

$31M65%

EMEA

$8M18%

Asia Pacific

$8M17%

Latin And Central America

$205,0000%